Chunling Liu

发表

Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly

Ying Cheng, Yanqiu Zhao, Xiaoqing Liu, 2019, Medicine.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.

N. Yang, Yu-Mei Shi, Shucai Zhang, 2022, The Lancet. Respiratory medicine.

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ying Cheng, S. Ramalingam, He-long Zhang, 2021, Targeted Oncology.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Ying Cheng, Dong Wang, Yuankai Shi, 2020 .

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China

Bo Yu, Chunling Liu, Xiaodan Zhu, 2022, OncoTargets and therapy.

OTT_A_381825 1021..1032

Bo Yu, Chunling Liu, Xiaodan Zhu, 2022 .

Activation of LncRNA HOTAIR by STAT3 Promotes Gefitinib Resistance and Tumourigenesis by Targeting MicroRNA-216a in NSCLC

Chunling Liu, Guomin Gu, Hongge Zhu, 2021 .

Mechanism of Abelmoschus manihot L. in the Treatment of Contrast-Induced Nephropathy on the Basis of Network Pharmacology Analysis

Yibei Wang, Chunling Liu, Zhongchi Xu, 2022, Frontiers in Nephrology.

Ef ﬁ cacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Lei Wang, Xueqin Chen, Wei Li, 2022 .

E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

Xiuli Wang, Chunling Liu, Guomin Gu, 2022, Laboratory Investigation.

LncRNA SNHG20 promoted proliferation, invasion and inhibited cell apoptosis of lung adenocarcinoma via sponging miR‐342 and upregulating DDX49

Xiuli Wang, Chunling Liu, Guomin Gu, 2020, Thoracic cancer.

Knockdown of Long Non-Coding RNA HOTAIR Suppresses Cisplatin Resistance, Cell Proliferation, Migration and Invasion of DDP-Resistant NSCLC Cells by Targeting miR-149-5p/Doublecortin-Like Kinase 1 Axis

Xiuli Wang, Chunling Liu, Yanli Shen, 2020, Cancer management and research.

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients

Y. Shang, Chunling Liu, Changjian Zhang, 2023, Frontiers in Oncology.

An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.

Xiuli Wang, Shune Yang, Chunling Liu, 2019, Acta biochimica et biophysica Sinica.

circ_0008797 attenuates non‐small cell lung cancer proliferation, metastasis, and aerobic glycolysis by sponging miR‐301a‐3p/SOCS2

Xiaodan Zhu, Chunling Liu, Yanli Shen, 2022, Environmental toxicology.

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy

Gang Sun, Chunling Liu, Xiaowen Wang, 2020, Experimental and therapeutic medicine.

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

Fei Liu, Jian Feng, N. Yang, 2023, BMC Medicine.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

Ef ﬁ cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

T. Wang, D. Zhong, Yanqiu Zhao, 2022 .

λ-Carrageenan improves the antitumor effect of dendritic cellbased vaccine

Jinyao Li, Jinyu Li, Chunling Liu, 2017, Oncotarget.

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

Ying Cheng, Dong Wang, Yuankai Shi, 2021, The Lancet. Respiratory medicine.

Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.

Xueqin Chen, L. Xing, S. Ren, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

He-long Zhang, Yunpeng Liu, Yanqiu Zhao, 2022, Signal Transduction and Targeted Therapy.

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

W. Feng, Tao Zhang, W. Liao, 2022, Frontiers in Medicine.

The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

A. Sanders, Xiuli Wang, Chunling Liu, 2018, Chemotherapy.

Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region

B. Zhao, Xiuli Wang, Chunling Liu, 2015, BMC Genetics.

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Xueqin Chen, H Zhao, Changli Wang, 2023, Nature Cancer.

Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study.

Jian-hua Chang, Si Sun, Juan Li, 2023, Lung cancer.

The concomitant EGFR T790M/C797S in trans and cis in three osimertinib-resistant lung adenocarcinoma patients.

Hailong Liu, Qixi Wu, Wang Jianwei, 2019, Journal of Clinical Oncology.

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

Shun Lu, Zhuang Yu, Zhehai Wang, 2021 .

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.

Chunling Liu, Xiaodan Zhu, Yan Zhao, 2023, Journal of cancer research and clinical oncology.

Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.

Fei Liu, Ying Cheng, Jian Feng, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).

Shun Lu, Yuping Sun, Zhuang Yu, 2022, Journal of Clinical Oncology.

Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region

B. Zhao, Xiuli Wang, Chunling Liu, 2015, BMC Genetics.